Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) insider Benjamin T. Dake sold 3,325 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $31.97, for a total value of $106,300.25. Following the sale, the insider now owns 1,291 shares of the company’s stock, valued at $41,273.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Aerovate Therapeutics Stock Performance
AVTE stock opened at $29.12 on Thursday. Aerovate Therapeutics, Inc. has a 1 year low of $9.41 and a 1 year high of $32.42. The firm has a market cap of $811.37 million, a P/E ratio of -10.11 and a beta of 1.23. The stock has a 50-day simple moving average of $22.98 and a 200-day simple moving average of $18.19.
Institutional Investors Weigh In On Aerovate Therapeutics
Large investors have recently modified their holdings of the stock. UBS Group AG acquired a new stake in shares of Aerovate Therapeutics in the third quarter valued at about $26,000. Tower Research Capital LLC TRC grew its stake in Aerovate Therapeutics by 136.2% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,702 shares of the company’s stock valued at $55,000 after purchasing an additional 1,558 shares in the last quarter. Citigroup Inc. grew its stake in Aerovate Therapeutics by 1,351.5% during the 2nd quarter. Citigroup Inc. now owns 3,324 shares of the company’s stock valued at $57,000 after purchasing an additional 3,095 shares in the last quarter. BNP Paribas Arbitrage SNC acquired a new stake in Aerovate Therapeutics during the 3rd quarter valued at approximately $66,000. Finally, Wells Fargo & Company MN grew its stake in Aerovate Therapeutics by 156.7% during the 2nd quarter. Wells Fargo & Company MN now owns 4,200 shares of the company’s stock valued at $72,000 after purchasing an additional 2,564 shares in the last quarter.
Analyst Upgrades and Downgrades
View Our Latest Analysis on AVTE
Aerovate Therapeutics Company Profile
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
- Five stocks we like better than Aerovate Therapeutics
- What Are Dividend Achievers? An Introduction
- Gold Rush: Exploring 5 Sector Giants Amidst Soaring Prices
- How to Use the MarketBeat Dividend Calculator
- What is a Bull Market? Key Information about Bull Markets
- The How And Why of Investing in Oil Stocks
- Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.